Elsevier

Kidney International

Volume 88, Issue 3, September 2015, Pages 447-459
Kidney International

Meeting Report
Executive summary of the KDIGO Controversies Conference on Supportive Care in Chronic Kidney Disease: developing a roadmap to improving quality care

https://doi.org/10.1038/ki.2015.110Get rights and content
Under an Elsevier user license
open archive

Patients with advanced chronic kidney disease (CKD) have a high burden of physical and psychosocial symptoms, poor outcomes, and high costs of care. Current paradigms of care for this highly vulnerable population are variable, prognostic and assessment tools are limited, and quality of care, particularly regarding conservative and palliative care, is suboptimal. The KDIGO Controversies Conference on Supportive Care in CKD reviewed the current state of knowledge in order to define a roadmap to guide clinical and research activities focused on improving the outcomes of people living with advanced CKD, including those on dialysis. An international group of multidisciplinary experts in CKD, palliative care, methodology, economics, and education identified the key issues related to palliative care in this population. The conference led to a working plan to address outstanding issues in this arena, and this executive summary serves as an output to guide future work, including the development of globally applicable guidelines.

Keywords

chronic kidney disease
conservative care
palliative care
supportive care
symptoms
withdrawal of dialysis

Cited by (0)

VJ declared having received research support from Baxter. EAB declared having received speaker honorarium and research support from Baxter. FEMM declared having received research support from UK National Institute for Health Research and UK Charity-Guy's & St Thomas Charity. RLM declared having received research support from Australian National Health and Medical Research Council, Cancer Australia, and Cancer Council NSW. GTO declared having received consultancy fees from AbbVie and Amgen; speaker honoraria from Abbott Nutrition, AbbVie and Amgen. SND, AL, AHM, FB, SN, MJG, and DJO'D reported no relevant disclosures.